Table 1.
Clinical characteristics of the 358 patients with locally advanced nasopharyngeal carcinoma (NPC)
| Characteristic | No. of patients | Percentage (%) |
|---|---|---|
| Age (years) | ||
| <50 | 232 | 64.8 |
| ≥50 | 126 | 35.2 |
| Sex | ||
| Male | 255 | 71.2 |
| Female | 103 | 28.8 |
| T categorya | ||
| T3 | 64 | 17.9 |
| T4 | 294 | 82.1 |
| N categorya | ||
| N0 | 66 | 18.4 |
| N1 | 113 | 31.6 |
| N2 | 118 | 33.0 |
| N3 | 61 | 17.0 |
| Tumor volume (mL) | ||
| ≤46.4 | 219 | 61.2 |
| >46.4 | 139 | 38.8 |
| WHO histological type | ||
| I | 25 | 7.0 |
| II–III | 333 | 93.0 |
| Chemotherapy | ||
| None | 21 | 5.9 |
| Concurrent or NACT or adjuvant | 47 | 13.1 |
| Concurrent + NACT | 39 | 10.9 |
| Concurrent + adjuvant | 10 | 2.8 |
| NACT + adjuvant | 92 | 25.7 |
| NACT + concurrent + adjuvant | 149 | 41.6 |
| Prescribed total dose (Gy) | ||
| <73.92 | 111 | 31.0 |
| ≥73.92 | 247 | 69.0 |
WHO World Health Organization, NACT neoadjuvant chemotherapy
aThe 7th American Joint Committee on Cancer (AJCC) staging system was used for T and N classification